The Government of the United Kingdom has stopped its Vaccine Contract Covid-19 with Valeva on a alleged violation of the obligations, the company announced Monday.
The French Society of Biotechnology stated in a statement that "received a report to terminate the Government of the United Kingdom (" HMG ") with regard to the supply contract for its candidate for the vaccine OVID19".
"HMG stated that the Company was in violation of its obligations under the procurement contract, but the company denies the titles:" He added.
Euronews contacted the Department of Brittany for Heath to comment.
Great Britain asked 100 million doses of the valley vaccine candidate, VLA2001 and had an option to ensure more than 90 million doses. The total amount of these 190 million doses is about 1.4 billion euros.
Jab is currently in phase 3 - which means it's actually being tested on thousands of people - with results expected early in the fourth quarter. Marketing is therefore planned before the end of the year.
The company began submitting its vaccine data for approval to the Medicines and Health Products Regulatory Authority (MHRA) last month and production of the vaccine began earlier this year at a production facility in Scotland "In order to optimize the progress of vaccine availability". VLA2001 is an inactivated, adjuvanted vaccine composed of all random viral particles of fully active SARSCoV2 mixed with two adjuvants to increase antibody levels. According to the company, the vaccine should meet standard cold chain requirements (2-8 ° C).
The UK regulator has so far approved four strands of Oxford / AstraZeneca, Pfizer / BioNTech, Moderna and Janssen.
To date, more than 89% of the UK population over the age of 16 have received at least one dose of the vaccine and 80.9% are fully immunized.
0 Comments